Disease-inducing potential of two leukemic cell lines in a xenografting model

Data de publicació: 01/06/2021 Data Ahead of Print: 01/03/2021

Autors de IIS La Fe

Sonia Herraiz Raya

Autor
Ana Buigues Lafuente

Autor
Antonio Pellicer Martínez

Autor
César Díaz García

Autor

Autors aliens a IIS La Fe

Manavella DD
Soares M
Donnez J
Dolmans MM

Grups d'Investigació

Medicina Reproductiva

Investigador Principal

José Morales Roselló

Abstract

Purpose Cryopreserved ovarian tissue transplant restores ovarian function in young cancer patients after gonadotoxic treatment. However, leukemia is associated with increased risk of malignant cell transmission. We aimed to assess the tumor-inducing potential of two different leukemic cell lines when xenografted to immunodeficient mice. Methods Fifty-four female immunodeficient mice were grafted with either 100, 200, 500, 1000, and 10,000 chronic myeloid leukemia in blast crisis (BV-173) cells or relapsed acute lymphoblastic leukemia (RCH-ACV) cells, embedded inside a fibrin scaffold along with 50,000 human ovarian stromal cells. Two mice per cell line received the fibrin matrix without leukemic cells as negative controls. Clinical signs of disease were monitored for 20 weeks. Grafts, liver tissue, and masses were collected for macroscopic analysis and gene expression of BCR-ABL1 and E2A-PBX fusion transcripts present in BV-173 and RCH-ACV respectively. Results BV-173 cells: Mice grafted with 100, 200, or 500 cells showed no sign of disease after and were negative for BCR-ABL1 expression. Three of the 5 animals grafted with 1000 cells and all mice with 10,000 cells developed disease and showed BCR-ABL1-positive expression. RCH-ACV cells: Two out of 4 mice grafted with 100 cells developed disease and were E2A-PBX1-positive. All the animals grafted with higher cell doses showed signs of disease and all but one were E2A-PBX1-positive. Conclusion The present work proves that the disease-inducing potential of BV-173 and RCH-ACV leukemic cells xenografted to SCID mouse peritoneum differs between cell lines, depending on cell number, type, status, and cytogenetic disease profile when ovarian tissue is harvested.

Dades de la publicació

ISSN/ISSNe:: 1058-0468, 1573-7330
Tipus:: Article
Pàgines:: 1589-1600
DOI:: 10.1007/s10815-021-02169-2
PubMed:: 33786735
Factor d'Impacte:: 1,109 SCImago ℠
Quartil:: Q1 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Manavella DD:: Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Rech Gynecol, Ave Mounier 52,Bte B1-52-02, B-1200 Brussels, Belgium

Neolife Med & Cirugia Reprod, Brasilia 760, Asuncion 1434, Paraguay
Herraiz S:: Instituto de Investigación. IVI Fdn Inst Invest Sanitaria Hosp La Fe IIS La F, Valencia, Spain
Soares M:: Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Rech Gynecol, Ave Mounier 52,Bte B1-52-02, B-1200 Brussels, Belgium
Buigues A:: Instituto de Investigación. IVI Fdn Inst Invest Sanitaria Hosp La Fe IIS La F, Valencia, Spain
Pellicer A:: Instituto de Investigación. IVI Fdn Inst Invest Sanitaria Hosp La Fe IIS La F, Valencia, Spain
Donnez J:: Soc Res Infertil, Brussels, Belgium
Díaz-García C:: Instituto de Investigación. IVI Fdn Inst Invest Sanitaria Hosp La Fe IIS La F, Valencia, Spain

IVI London, IVIRMA Global, London W1G 9RQ, England

UCL, Dept Reprod Hlth, London WC1E 6AU, England
Dolmans MM:: Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Rech Gynecol, Ave Mounier 52,Bte B1-52-02, B-1200 Brussels, Belgium

Clin Univ St Luc, Dept Gynecol, B-1200 Brussels, Belgium